Trial Profile

A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of CMP-CPS-001 in Healthy Volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CMPCPS 001 (Primary)
Indications Inborn urea cycle disorders
Focus Adverse reactions; First in man
Sponsors CAMP4 Therapeutics

Most Recent Events

16 May 2025 According to CAMP4 Therapeutics Corp. media release, Dosing completed in MAD Cohort 1 through Cohort 3.
16 May 2025 Results presented in the CAMP4 Therapeutics Corp. media release.
16 May 2025 According to CAMP4 Therapeutics Corp. media release, data from this trial was at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, May 13 to 17, 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com